Romidepsin
Leukemia, Myeloid
Dartmouth-Hitchcock Medical CenterSmall moleculePhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Leukemia, Myeloid cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 3 | BB |
ETOPOSIDE Instituto de Investigación Hospital Universitario La Paz | Phase 2 | B |
Enasidenib Tian Yi Zhang | Phase 3 | B |
Azacitidine Jacqueline Garcia, MD | Phase 3 | B |
Daunorubicin Kanisa Pharmaceuticals | Phase 2/3 | B |
View all 37 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →